A phase Ia trial investigating SNS-062 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2016
At a glance
- Drugs SNS 062 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; First in man
- Sponsors Sunesis Pharmaceuticals
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 05 Dec 2016 Results published in a Sunesis Pharmaceuticals media release.
- 05 Dec 2016 Status changed from recruiting to completed, as reported in a Sunesis Pharmaceuticals media release.